查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1584678

中枢神经系统治疗市场：按疾病、药物类型、给药途径、最终用户分类 - 全球预测 2025-2030

Central Nervous System Therapeutics Market by Disorders (Epileptic Disorders, Neurodegenerative Diseases, Pain Management), Drug Type (Biologics, Small Molecules), Route of Administration, End-Users - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 192 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

中枢神经系统治疗市场2023年估值为1,338.3亿美元，预计2024年将达1,431.1亿美元，复合年增长率为7.24%，到2030年将达2,184.5亿美元，预计将达到1美元。

中枢神经系统（CNS）治疗市场包括针对神经系统疾病和疾病的多种治疗方法，例如阿兹海默症、帕金森氏症、多发性硬化症和忧郁症。由于人口老化、意识提高和医疗保健普及，神经系统疾病的盛行率不断上升，推动了该市场的发展。这些疾病造成的巨大社会和经济负担强调了对中枢神经系统治疗的需求，因此创新的治疗选择和改善患者的治疗结果至关重要。应用多种多样，包括药物、基因和细胞疗法，以及针对急性和慢性中枢神经系统疾病的创新递送系统。主要最终用户包括医院、诊所和研究机构。市场成长受到药物输送技术的进步、诊断技术的改进以及新型生技药品的涌入的影响。寻求个人化医疗的机会比比皆是，重点是基因组学来创造标靶治疗。研究和开发的合作、在药物发现中使用人工智慧以及孤儿药指定等监管激励措施是利用新兴机会的潜在途径。然而，该市场面临研发成本高、监管环境严格以及基础设施障碍导致渗透新兴地区的挑战等限制。此外，缺乏预测模型和系统以及穿过血脑障壁的困难仍然是持续存在的挑战。为了解决这些问题，生物标记的创新、改进的临床试验设计和脑支架技术可以带来改变。中枢神经系统治疗市场的动态、高风险、高回报性质需要持续创新和敏捷性。鼓励公司投资合作研究，培养策略伙伴关係，利用技术进步，同时应对监管和营运挑战。透过专注于全面的患者照护解决方案并利用数位健康技术，我们相信我们可以在这个不断发展的环境中创造永续的竞争优势。

主要市场统计
基准年[2023] 1338.3亿美元
预测年份 [2024] 1431.1亿美元
预测年份 [2030] 2184.5亿美元
复合年增长率（%） 7.24%

市场动态：快速发展的中枢神经系统治疗市场的关键市场洞察

供需的动态交互作用正在改变中枢神经系统治疗市场。透过了解这些不断变化的市场动态，公司可以准备好做出明智的投资决策、完善策略决策并抓住新的商机。全面了解这些趋势可以帮助企业降低政治、地理、技术、社会和经济领域的风险，同时消费行为及其对製造成本的影响以及对采购趋势的影响。

  • 市场驱动因素
    • 老年人口增加和神经退化性疾病盛行率
    • 政府对神经系统疾病研究的措施和资助
  • 市场限制因素
    • 与中枢神经系统疾病相关的产品案例增加
  • 市场机会
    • 投资神经退化性疾病的基因编辑技术与干细胞研究
    • 使用奈米材料创新药物配方的可能性
  • 市场挑战
    • 中枢神经系统疾病复杂且难以穿越血脑障壁

波特五力：驾驭中枢神经系统药物市场的策略工具

波特的五力框架是理解市场竞争格局的重要工具。波特的五力框架为评估公司的竞争地位和探索策略机会提供了清晰的方法。该框架可帮助公司评估市场动态并确定新业务的盈利。这些见解使公司能够利用自己的优势，解决弱点并避免潜在的挑战，从而确保更强大的市场地位。

PESTLE分析：了解对中枢神经系统治疗市场的外部影响

外部宏观环境因素在塑造中枢神经系统治疗市场的绩效动态方面发挥着至关重要的作用。对政治、经济、社会、技术、法律和环境因素的分析提供了应对这些影响所需的资讯。透过调查 PESTLE 因素，公司可以更了解潜在的风险和机会。这种分析可以帮助公司预测法规、消费者偏好和经济趋势的变化，并帮助他们做出积极主动的决策。

市场占有率分析 了解中枢神经系统治疗市场的竞争状况

中枢神经系统治疗市场的详细市场占有率分析可以对供应商绩效进行全面评估。公司可以透过比较收益、客户群和成长率等关键指标来揭示其竞争地位。该分析揭示了市场集中、分散和整合的趋势，为供应商提供了製定策略决策所需的洞察力，使他们能够在日益激烈的竞争中占有一席之地。

FPNV 定位矩阵中枢神经系统治疗市场供应商的绩效评估

FPNV定位矩阵是评估中枢神经系统治疗市场供应商的重要工具。此矩阵允许业务组织根据供应商的商务策略和产品满意度评估供应商，从而做出符合其目标的明智决策。这四个象限使您能够清晰、准确地划分供应商，并确定最能满足您的策略目标的合作伙伴和解决方案。

策略分析与建议，规划中枢神经系统治疗市场的成功之路

对于希望加强在全球市场的影响力的公司来说，中枢神经系统药物市场的策略分析至关重要。透过审查关键资源、能力和绩效指标，公司可以识别成长机会并努力改进。这种方法使您能够克服竞争环境中的挑战，利用新的商机，并取得长期成功。

本报告对市场进行了全面分析，涵盖关键重点领域：

1. 市场渗透率：对当前市场环境的详细审查、主要企业的广泛资料、对其在市场中的影响力和整体影响力的评估。

2. 市场开拓：辨识新兴市场的成长机会，评估现有领域的扩张潜力，并提供未来成长的策略蓝图。

3. 市场多元化：分析近期产品发布、开拓地区、关键产业进展、塑造市场的策略投资。

4. 竞争评估与情报：彻底分析竞争格局，检验市场占有率、业务策略、产品系列、认证、监理核准、专利趋势、主要企业的技术进步等。

5. 产品开发与创新：重点在于有望推动未来市场成长的最尖端科技、研发活动和产品创新。

我们也回答重要问题，以帮助相关人员做出明智的决策：

1.目前的市场规模和未来的成长预测是多少？

2. 哪些产品、区隔市场和地区提供最佳投资机会？

3.塑造市场的主要技术趋势和监管影响是什么？

4.主要厂商的市场占有率和竞争地位如何？

5. 推动供应商市场进入和退出策略的收益来源和策略机会是什么？

目录

第一章 前言

第二章调查方法

第三章执行摘要

第四章市场概况

第五章市场洞察

  • 市场动态
    • 促进因素
      • 老年人口的增加和神经退化性疾病的传播
      • 实施政府措施及资助神经系统疾病研究
    • 抑制因素
      • 与中枢神经系统药物相关的产品召回增加
    • 机会
      • 投资神经退化性疾病的基因编辑技术与干细胞研究
      • 奈米材料在创新药物配方中的潜在用途
    • 任务
      • 中枢神经系统疾病复杂且难以穿越血脑障壁
  • 市场区隔分析
    • 疾病：癫痫盛行率不断上升，医疗需求未被满足
    • 药物类型：用于特异性和强效治疗的创新生物製药
    • 给药途径：由于其长效配方，注射剂是优选的。
    • 最终用户：医院对用于即时干预的中枢神经系统疗法有巨大的需求。
  • 波特五力分析
  • PESTEL分析
    • 政治的
    • 经济
    • 社群
    • 技术的
    • 合法地
    • 环境

第六章中枢神经系统治疗药物市场秩序混乱

  • 癫痫症
    • 癫痫
    • 癫痫症
  • 神经退化性疾病
    • 阿兹海默症
    • 肌萎缩侧索硬化症
    • 多发性硬化症
    • 帕金森氏症
  • 疼痛管理
    • 急性疼痛
    • 慢性疼痛
    • 神经病变疼痛
  • 精神疾病
    • 焦虑症
    • 躁郁症
    • 忧郁症
    • 思觉失调症

第七章依药物类型分類的中枢神经系统治疗药物市场

  • 生物製药
    • 基因治疗
    • 单株抗体
    • 胜肽
    • 干细胞疗法
  • 小分子

第八章中枢神经系统治疗市场：依给药途径

  • 可注射的
    • 肌肉注射
    • 静脉
    • 皮下的
  • 口服
  • 经皮的

第九章中枢神经系统治疗市场：依最终用户分类

  • 医院
  • 调查机构
  • 专科诊所

第十章北美和南美中枢神经系统治疗药物市场

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美国

第十一章亚太地区中枢神经系统治疗市场

  • 澳洲
  • 中国
  • 印度
  • 印尼
  • 日本
  • 马来西亚
  • 菲律宾
  • 新加坡
  • 韩国
  • 台湾
  • 泰国
  • 越南

第十二章欧洲、中东和非洲中枢神经系统治疗药物市场

  • 丹麦
  • 埃及
  • 芬兰
  • 法国
  • 德国
  • 以色列
  • 义大利
  • 荷兰
  • 奈及利亚
  • 挪威
  • 波兰
  • 卡达
  • 俄罗斯
  • 沙乌地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公国
  • 英国

第十三章竞争格局

  • 2023 年市场占有率分析
  • FPNV 定位矩阵，2023
  • 竞争场景分析
    • Amneal Pharmaceuticals 获得 FDA核准CREXONT 增强帕金森氏症治疗
    • Asen Neuron 获得 1 亿美元资金用于开发神经退化性疾病治疗药物 ASN51
    • 礼来公司的 Xanra 获得 FDA核准用于阿兹海默症的早期治疗
    • 罗氏与 Acidian Therapeutics 合作开发针对神经系统疾病的创新 RNA治疗方法
    • Voyager Therapeutics 开始阿兹海默症药物 VY-TAU01 的 1a 期试验
    • Supernus Pharmaceuticals接受FDA 关于 SPN-830 的完整回覆信
    • 赛诺菲印度公司与 Cipla 合作，加强中枢神经系统治疗药物的分销和推广，以改善患者的治疗效果。
    • Engrail Therapeutics 获得 1.57 亿美元 B 轮资金筹措，以推进非成瘾性中枢神经系统疗法并扩大战略伙伴关係
    • Myrobalan Therapeutics 获得 2,400 万美元 A 轮资金筹措，以推进中枢神经系统治疗
    • 艾伯维 (AbbVie) 在欧盟推出 Produodopa，这是一种革命性的 24 小时皮下输注疗法，用于治疗进行性帕金森氏症
    • 4D Molecular Therapeutics 和 Arbor Biotechnologies 合作推进中枢神经系统疾病的创新基因疗法
    • MapLight Therapeutics 获得 2.25 亿美元 C 轮资金筹措，以推进中枢神经系统治疗
    • Pharmanovia 收购赛诺菲 11 个 CNS 品牌，扩大神经科产品组合
    • 诺华以 5 亿美元收购专注于 siRNA 的 DTx Pharma，加强神经科学产品线
    • Neurocrine Biosciences 与 Voyager Therapeutics 合作价值 1.75 亿美元的基因疗法交易
  • 战略分析和建议
    • F.霍夫曼拉罗氏股份公司
    • 百时美施贵宝公司
    • 羽扇豆有限公司
    • 艾伯维公司

公司名单

  • AbbVie Inc.
  • AC Immune SA
  • Acadia Pharmaceuticals Inc.
  • Acorda Therapeutics, Inc.
  • Alkermes PLC
  • Amgen Inc.
  • AstraZeneca PLC
  • Bayer AG
  • Biogen Inc.
  • Bristol-Myers Squibb Company
  • CH Boehringer Sohn AG & Co. KG
  • Cassava Sciences, Inc.
  • Cipla Limited
  • CNS Pharmaceuticals, Inc.
  • Denali Therapeutics Inc.
  • Eisai Co. Ltd.
  • Eli Lilly and Company
  • F. Hoffmann-La Roche AG
  • GlaxoSmithKline PLC
  • H. Lundbeck A/S
  • Intra-Cellular Therapies, Inc.
  • Ipsen SA
  • Johnson & Johnson Services, Inc.
  • Lupin Limited
  • MapLight Therapeutics, Inc.
  • Merck KGaA
  • Minerva Neurosciences, Inc.
  • Neuraxpharm
  • Novartis AG
  • Novo Nordisk A/S
  • Otsuka Holdings Co Ltd
  • Pfizer Inc.
  • Polpharma Biologics SA
  • Rapport Therapeutics, Inc.
  • Sage Therapeutics, Inc.
  • Sanofi SA
  • Sun Pharmaceutical Industries Limited
  • Supernus Pharmaceuticals, Inc.
  • Takeda Pharmaceutical Company Limited
  • TauRx Pharmaceuticals Ltd
  • Teva Pharmaceutical Industries Ltd.
  • UCB SA
Product Code: MRR-02026C4C9A19

The Central Nervous System Therapeutics Market was valued at USD 133.83 billion in 2023, expected to reach USD 143.11 billion in 2024, and is projected to grow at a CAGR of 7.24%, to USD 218.45 billion by 2030.

The Central Nervous System (CNS) Therapeutics market encompasses a broad range of treatments targeting neurological disorders and diseases, including Alzheimer's, Parkinson's, multiple sclerosis, and depression. This market is driven by the increasing prevalence of neurological disorders due to aging populations, rising awareness, and expanding healthcare access. The necessity for CNS therapeutics is underscored by the significant social and economic burden posed by these diseases, making innovative treatment options and improved patient outcomes critical. Applications span across pharmaceuticals, gene and cell therapies, and innovative delivery systems, catering to both acute and chronic aspects of CNS disorders. Key end-users include hospitals, clinics, and research institutions. Market growth is influenced by advancements in drug delivery technologies, improved diagnostic techniques, and an influx of novel biologics. Opportunities abound in the exploration of personalized medicine, with a focus on genomics to create targeted therapies. Collaborative efforts in R&D, artificial intelligence utilization for drug discovery, and regulatory incentives like orphan drug designation are potential routes to capitalize on burgeoning opportunities. However, the market faces limitations such as significant R&D costs, stringent regulatory landscapes, and challenges in penetrating developing regions due to infrastructure hurdles. The scarcity of predictive model systems and difficulty in crossing the blood-brain barrier remain persistent challenges. To address these, innovation in biomarkers, improved clinical trial designs, and brain scaffold technologies could be transformative. The nature of the CNS therapeutics market is dynamic, with a high-risk, high-reward profile demanding continuous innovation and agility. Companies are advised to invest in collaborative research, foster strategic partnerships, and leverage technological advancements while navigating the regulatory and operational challenges. Focusing on comprehensive patient care solutions and leveraging digital health technologies could create a sustainable competitive edge in this evolving landscape.

KEY MARKET STATISTICS
Base Year [2023] USD 133.83 billion
Estimated Year [2024] USD 143.11 billion
Forecast Year [2030] USD 218.45 billion
CAGR (%) 7.24%

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Central Nervous System Therapeutics Market

The Central Nervous System Therapeutics Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Growing elderly population and the prevalence of neurodegenerative disorders
    • Implementation of government initiatives & funding for research on neurological disorders
  • Market Restraints
    • Rising cases of product recall associated with the CNS drugs
  • Market Opportunities
    • Investment in gene-editing technologies and stem cell research for neurodegenerative diseases
    • Potential utilization of nanomaterials for innovative drug formulation
  • Market Challenges
    • Complexities of CNS disorders coupled with difficulty in crossing the blood-brain barrier

Porter's Five Forces: A Strategic Tool for Navigating the Central Nervous System Therapeutics Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Central Nervous System Therapeutics Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Central Nervous System Therapeutics Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Central Nervous System Therapeutics Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Central Nervous System Therapeutics Market

A detailed market share analysis in the Central Nervous System Therapeutics Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Central Nervous System Therapeutics Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Central Nervous System Therapeutics Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Central Nervous System Therapeutics Market

A strategic analysis of the Central Nervous System Therapeutics Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Central Nervous System Therapeutics Market, highlighting leading vendors and their innovative profiles. These include AbbVie Inc., AC Immune SA, Acadia Pharmaceuticals Inc., Acorda Therapeutics, Inc., Alkermes PLC, Amgen Inc., AstraZeneca PLC, Bayer AG, Biogen Inc., Bristol-Myers Squibb Company, C.H. Boehringer Sohn AG & Co. KG, Cassava Sciences, Inc., Cipla Limited, CNS Pharmaceuticals, Inc., Denali Therapeutics Inc., Eisai Co. Ltd., Eli Lilly and Company, F. Hoffmann-La Roche AG, GlaxoSmithKline PLC, H. Lundbeck A/S, Intra-Cellular Therapies, Inc., Ipsen S.A., Johnson & Johnson Services, Inc., Lupin Limited, MapLight Therapeutics, Inc., Merck KGaA, Minerva Neurosciences, Inc., Neuraxpharm, Novartis AG, Novo Nordisk A/S, Otsuka Holdings Co Ltd, Pfizer Inc., Polpharma Biologics S.A., Rapport Therapeutics, Inc., Sage Therapeutics, Inc., Sanofi S.A., Sun Pharmaceutical Industries Limited, Supernus Pharmaceuticals, Inc., Takeda Pharmaceutical Company Limited, TauRx Pharmaceuticals Ltd, Teva Pharmaceutical Industries Ltd., and UCB S.A..

Market Segmentation & Coverage

This research report categorizes the Central Nervous System Therapeutics Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Disorders, market is studied across Epileptic Disorders, Neurodegenerative Diseases, Pain Management, and Psychiatric Disorders. The Epileptic Disorders is further studied across Epilepsy and Seizure Disorders. The Neurodegenerative Diseases is further studied across Alzheimer's Disease, Amyotrophic Lateral Sclerosis, Multiple Sclerosis, and Parkinson's Disease. The Pain Management is further studied across Acute Pain, Chronic Pain, and Neuropathic Pain. The Psychiatric Disorders is further studied across Anxiety Disorders, Bipolar Disorder, Depression, and Schizophrenia.
  • Based on Drug Type, market is studied across Biologics and Small Molecules. The Biologics is further studied across Gene Therapies, Monoclonal Antibodies, Peptides, and Stem Cell Therapies.
  • Based on Route of Administration, market is studied across Injectable, Oral, and Transdermal. The Injectable is further studied across Intramuscular, Intravenous, and Subcutaneous.
  • Based on End-Users, market is studied across Hospitals, Research Institutes, and Specialty Clinics.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Growing elderly population and the prevalence of neurodegenerative disorders
      • 5.1.1.2. Implementation of government initiatives & funding for research on neurological disorders
    • 5.1.2. Restraints
      • 5.1.2.1. Rising cases of product recall associated with the CNS drugs
    • 5.1.3. Opportunities
      • 5.1.3.1. Investment in gene-editing technologies and stem cell research for neurodegenerative diseases
      • 5.1.3.2. Potential utilization of nanomaterials for innovative drug formulation
    • 5.1.4. Challenges
      • 5.1.4.1. Complexities of CNS disorders coupled with difficulty in crossing the blood-brain barrier
  • 5.2. Market Segmentation Analysis
    • 5.2.1. Disorders: Increasing epileptic disorder prevalence and significant unmet medical needs
    • 5.2.2. Drug Type: Innovative biologics for particular and potent treatments
    • 5.2.3. Route of Administration: High preference for injectable routes owing to their long-acting formulations
    • 5.2.4. End-Users: Significant demand for CNS therapeutics in hospitals for immediate interventions
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Central Nervous System Therapeutics Market, by Disorders

  • 6.1. Introduction
  • 6.2. Epileptic Disorders
    • 6.2.1. Epilepsy
    • 6.2.2. Seizure Disorders
  • 6.3. Neurodegenerative Diseases
    • 6.3.1. Alzheimer's Disease
    • 6.3.2. Amyotrophic Lateral Sclerosis
    • 6.3.3. Multiple Sclerosis
    • 6.3.4. Parkinson's Disease
  • 6.4. Pain Management
    • 6.4.1. Acute Pain
    • 6.4.2. Chronic Pain
    • 6.4.3. Neuropathic Pain
  • 6.5. Psychiatric Disorders
    • 6.5.1. Anxiety Disorders
    • 6.5.2. Bipolar Disorder
    • 6.5.3. Depression
    • 6.5.4. Schizophrenia

7. Central Nervous System Therapeutics Market, by Drug Type

  • 7.1. Introduction
  • 7.2. Biologics
    • 7.2.1. Gene Therapies
    • 7.2.2. Monoclonal Antibodies
    • 7.2.3. Peptides
    • 7.2.4. Stem Cell Therapies
  • 7.3. Small Molecules

8. Central Nervous System Therapeutics Market, by Route of Administration

  • 8.1. Introduction
  • 8.2. Injectable
    • 8.2.1. Intramuscular
    • 8.2.2. Intravenous
    • 8.2.3. Subcutaneous
  • 8.3. Oral
  • 8.4. Transdermal

9. Central Nervous System Therapeutics Market, by End-Users

  • 9.1. Introduction
  • 9.2. Hospitals
  • 9.3. Research Institutes
  • 9.4. Specialty Clinics

10. Americas Central Nervous System Therapeutics Market

  • 10.1. Introduction
  • 10.2. Argentina
  • 10.3. Brazil
  • 10.4. Canada
  • 10.5. Mexico
  • 10.6. United States

11. Asia-Pacific Central Nervous System Therapeutics Market

  • 11.1. Introduction
  • 11.2. Australia
  • 11.3. China
  • 11.4. India
  • 11.5. Indonesia
  • 11.6. Japan
  • 11.7. Malaysia
  • 11.8. Philippines
  • 11.9. Singapore
  • 11.10. South Korea
  • 11.11. Taiwan
  • 11.12. Thailand
  • 11.13. Vietnam

12. Europe, Middle East & Africa Central Nervous System Therapeutics Market

  • 12.1. Introduction
  • 12.2. Denmark
  • 12.3. Egypt
  • 12.4. Finland
  • 12.5. France
  • 12.6. Germany
  • 12.7. Israel
  • 12.8. Italy
  • 12.9. Netherlands
  • 12.10. Nigeria
  • 12.11. Norway
  • 12.12. Poland
  • 12.13. Qatar
  • 12.14. Russia
  • 12.15. Saudi Arabia
  • 12.16. South Africa
  • 12.17. Spain
  • 12.18. Sweden
  • 12.19. Switzerland
  • 12.20. Turkey
  • 12.21. United Arab Emirates
  • 12.22. United Kingdom

13. Competitive Landscape

  • 13.1. Market Share Analysis, 2023
  • 13.2. FPNV Positioning Matrix, 2023
  • 13.3. Competitive Scenario Analysis
    • 13.3.1. Amneal Pharmaceuticals receives FDA approval for CREXONT to enhance Parkinson's therapy
    • 13.3.2. Asceneuron secures USD 100M to advance ASN51 for neurodegenerative diseases
    • 13.3.3. Eli Lilly's Kisunla receives FDA approval for early Alzheimer's treatment
    • 13.3.4. Roche and Ascidian Therapeutics join forces to develop innovative RNA therapies for neurological diseases
    • 13.3.5. Voyager Therapeutics initiates Phase 1a trial of VY-TAU01 for Alzheimer's
    • 13.3.6. Supernus Pharmaceuticals receives FDA Complete Response Letter for SPN-830
    • 13.3.7. Sanofi India partners with Cipla to enhance distribution and promotion of CNS therapeutics to improve patient outcomes
    • 13.3.8. Engrail Therapeutics secures USD 157M Series B funding to advance non-addictive CNS therapies and expand strategic partnerships
    • 13.3.9. Myrobalan Therapeutics secures USD 24 million in Series A funding to advance CNS treatments
    • 13.3.10. AbbVie launches Produodopa, a groundbreaking 24-hour subcutaneous infusion therapy for advanced Parkinson's in the EU
    • 13.3.11. 4D Molecular Therapeutics and Arbor Biotechnologies partner to advance innovative genetic therapies for CNS disorders
    • 13.3.12. MapLight Therapeutics secures USD 225 million Series C funding to advance CNS therapies
    • 13.3.13. Pharmanovia expands neurology portfolio by acquiring 11 CNS brands from Sanofi
    • 13.3.14. Novartis strengthens neuroscience pipeline with USD 500M acquisition of siRNA-focused DTx Pharma
    • 13.3.15. Neurocrine Biosciences collaborates with Voyager Therapeutics on USD 175M gene therapy deal
  • 13.4. Strategy Analysis & Recommendation
    • 13.4.1. F. Hoffmann-La Roche AG
    • 13.4.2. Bristol-Myers Squibb Company
    • 13.4.3. Lupin Limited
    • 13.4.4. AbbVie Inc.

Companies Mentioned

  • 1. AbbVie Inc.
  • 2. AC Immune SA
  • 3. Acadia Pharmaceuticals Inc.
  • 4. Acorda Therapeutics, Inc.
  • 5. Alkermes PLC
  • 6. Amgen Inc.
  • 7. AstraZeneca PLC
  • 8. Bayer AG
  • 9. Biogen Inc.
  • 10. Bristol-Myers Squibb Company
  • 11. C.H. Boehringer Sohn AG & Co. KG
  • 12. Cassava Sciences, Inc.
  • 13. Cipla Limited
  • 14. CNS Pharmaceuticals, Inc.
  • 15. Denali Therapeutics Inc.
  • 16. Eisai Co. Ltd.
  • 17. Eli Lilly and Company
  • 18. F. Hoffmann-La Roche AG
  • 19. GlaxoSmithKline PLC
  • 20. H. Lundbeck A/S
  • 21. Intra-Cellular Therapies, Inc.
  • 22. Ipsen S.A.
  • 23. Johnson & Johnson Services, Inc.
  • 24. Lupin Limited
  • 25. MapLight Therapeutics, Inc.
  • 26. Merck KGaA
  • 27. Minerva Neurosciences, Inc.
  • 28. Neuraxpharm
  • 29. Novartis AG
  • 30. Novo Nordisk A/S
  • 31. Otsuka Holdings Co Ltd
  • 32. Pfizer Inc.
  • 33. Polpharma Biologics S.A.
  • 34. Rapport Therapeutics, Inc.
  • 35. Sage Therapeutics, Inc.
  • 36. Sanofi S.A.
  • 37. Sun Pharmaceutical Industries Limited
  • 38. Supernus Pharmaceuticals, Inc.
  • 39. Takeda Pharmaceutical Company Limited
  • 40. TauRx Pharmaceuticals Ltd
  • 41. Teva Pharmaceutical Industries Ltd.
  • 42. UCB S.A.

LIST OF FIGURES

  • FIGURE 1. CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET RESEARCH PROCESS
  • FIGURE 2. CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY DISORDERS, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY DISORDERS, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2023 VS 2030 (%)
  • FIGURE 11. GLOBAL CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. GLOBAL CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY END-USERS, 2023 VS 2030 (%)
  • FIGURE 13. GLOBAL CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY END-USERS, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. AMERICAS CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 15. AMERICAS CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. UNITED STATES CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 17. UNITED STATES CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. ASIA-PACIFIC CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 19. ASIA-PACIFIC CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 20. EUROPE, MIDDLE EAST & AFRICA CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 21. EUROPE, MIDDLE EAST & AFRICA CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 22. CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 23. CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET DYNAMICS
  • TABLE 7. GLOBAL CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY EPILEPTIC DISORDERS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY EPILEPSY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY SEIZURE DISORDERS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY EPILEPTIC DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY NEURODEGENERATIVE DISEASES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY ALZHEIMER'S DISEASE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY AMYOTROPHIC LATERAL SCLEROSIS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY MULTIPLE SCLEROSIS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY PARKINSON'S DISEASE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY NEURODEGENERATIVE DISEASES, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY PAIN MANAGEMENT, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 19. GLOBAL CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY ACUTE PAIN, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 20. GLOBAL CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY CHRONIC PAIN, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 21. GLOBAL CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY NEUROPATHIC PAIN, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 22. GLOBAL CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY PAIN MANAGEMENT, 2018-2030 (USD MILLION)
  • TABLE 23. GLOBAL CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY PSYCHIATRIC DISORDERS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 24. GLOBAL CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY ANXIETY DISORDERS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 25. GLOBAL CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY BIPOLAR DISORDER, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 26. GLOBAL CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY DEPRESSION, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 27. GLOBAL CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY SCHIZOPHRENIA, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 28. GLOBAL CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY PSYCHIATRIC DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 29. GLOBAL CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 30. GLOBAL CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY BIOLOGICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 31. GLOBAL CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY GENE THERAPIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 32. GLOBAL CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 33. GLOBAL CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY PEPTIDES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 34. GLOBAL CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY STEM CELL THERAPIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 35. GLOBAL CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
  • TABLE 36. GLOBAL CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY SMALL MOLECULES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 37. GLOBAL CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 38. GLOBAL CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY INJECTABLE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 39. GLOBAL CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY INTRAMUSCULAR, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 40. GLOBAL CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 41. GLOBAL CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY SUBCUTANEOUS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 42. GLOBAL CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY INJECTABLE, 2018-2030 (USD MILLION)
  • TABLE 43. GLOBAL CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY ORAL, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 44. GLOBAL CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY TRANSDERMAL, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 45. GLOBAL CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 46. GLOBAL CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 47. GLOBAL CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY RESEARCH INSTITUTES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 48. GLOBAL CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 49. AMERICAS CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 50. AMERICAS CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY EPILEPTIC DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 51. AMERICAS CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY NEURODEGENERATIVE DISEASES, 2018-2030 (USD MILLION)
  • TABLE 52. AMERICAS CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY PAIN MANAGEMENT, 2018-2030 (USD MILLION)
  • TABLE 53. AMERICAS CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY PSYCHIATRIC DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 54. AMERICAS CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 55. AMERICAS CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
  • TABLE 56. AMERICAS CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 57. AMERICAS CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY INJECTABLE, 2018-2030 (USD MILLION)
  • TABLE 58. AMERICAS CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 59. AMERICAS CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 60. ARGENTINA CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 61. ARGENTINA CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY EPILEPTIC DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 62. ARGENTINA CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY NEURODEGENERATIVE DISEASES, 2018-2030 (USD MILLION)
  • TABLE 63. ARGENTINA CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY PAIN MANAGEMENT, 2018-2030 (USD MILLION)
  • TABLE 64. ARGENTINA CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY PSYCHIATRIC DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 65. ARGENTINA CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 66. ARGENTINA CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
  • TABLE 67. ARGENTINA CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 68. ARGENTINA CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY INJECTABLE, 2018-2030 (USD MILLION)
  • TABLE 69. ARGENTINA CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 70. BRAZIL CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 71. BRAZIL CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY EPILEPTIC DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 72. BRAZIL CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY NEURODEGENERATIVE DISEASES, 2018-2030 (USD MILLION)
  • TABLE 73. BRAZIL CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY PAIN MANAGEMENT, 2018-2030 (USD MILLION)
  • TABLE 74. BRAZIL CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY PSYCHIATRIC DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 75. BRAZIL CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 76. BRAZIL CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
  • TABLE 77. BRAZIL CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 78. BRAZIL CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY INJECTABLE, 2018-2030 (USD MILLION)
  • TABLE 79. BRAZIL CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 80. CANADA CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 81. CANADA CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY EPILEPTIC DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 82. CANADA CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY NEURODEGENERATIVE DISEASES, 2018-2030 (USD MILLION)
  • TABLE 83. CANADA CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY PAIN MANAGEMENT, 2018-2030 (USD MILLION)
  • TABLE 84. CANADA CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY PSYCHIATRIC DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 85. CANADA CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 86. CANADA CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
  • TABLE 87. CANADA CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 88. CANADA CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY INJECTABLE, 2018-2030 (USD MILLION)
  • TABLE 89. CANADA CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 90. MEXICO CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 91. MEXICO CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY EPILEPTIC DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 92. MEXICO CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY NEURODEGENERATIVE DISEASES, 2018-2030 (USD MILLION)
  • TABLE 93. MEXICO CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY PAIN MANAGEMENT, 2018-2030 (USD MILLION)
  • TABLE 94. MEXICO CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY PSYCHIATRIC DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 95. MEXICO CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 96. MEXICO CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
  • TABLE 97. MEXICO CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 98. MEXICO CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY INJECTABLE, 2018-2030 (USD MILLION)
  • TABLE 99. MEXICO CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 100. UNITED STATES CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 101. UNITED STATES CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY EPILEPTIC DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 102. UNITED STATES CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY NEURODEGENERATIVE DISEASES, 2018-2030 (USD MILLION)
  • TABLE 103. UNITED STATES CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY PAIN MANAGEMENT, 2018-2030 (USD MILLION)
  • TABLE 104. UNITED STATES CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY PSYCHIATRIC DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 105. UNITED STATES CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 106. UNITED STATES CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
  • TABLE 107. UNITED STATES CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 108. UNITED STATES CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY INJECTABLE, 2018-2030 (USD MILLION)
  • TABLE 109. UNITED STATES CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 110. UNITED STATES CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 111. ASIA-PACIFIC CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 112. ASIA-PACIFIC CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY EPILEPTIC DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 113. ASIA-PACIFIC CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY NEURODEGENERATIVE DISEASES, 2018-2030 (USD MILLION)
  • TABLE 114. ASIA-PACIFIC CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY PAIN MANAGEMENT, 2018-2030 (USD MILLION)
  • TABLE 115. ASIA-PACIFIC CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY PSYCHIATRIC DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 116. ASIA-PACIFIC CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 117. ASIA-PACIFIC CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
  • TABLE 118. ASIA-PACIFIC CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 119. ASIA-PACIFIC CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY INJECTABLE, 2018-2030 (USD MILLION)
  • TABLE 120. ASIA-PACIFIC CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 121. ASIA-PACIFIC CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 122. AUSTRALIA CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 123. AUSTRALIA CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY EPILEPTIC DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 124. AUSTRALIA CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY NEURODEGENERATIVE DISEASES, 2018-2030 (USD MILLION)
  • TABLE 125. AUSTRALIA CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY PAIN MANAGEMENT, 2018-2030 (USD MILLION)
  • TABLE 126. AUSTRALIA CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY PSYCHIATRIC DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 127. AUSTRALIA CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 128. AUSTRALIA CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
  • TABLE 129. AUSTRALIA CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 130. AUSTRALIA CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY INJECTABLE, 2018-2030 (USD MILLION)
  • TABLE 131. AUSTRALIA CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 132. CHINA CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 133. CHINA CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY EPILEPTIC DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 134. CHINA CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY NEURODEGENERATIVE DISEASES, 2018-2030 (USD MILLION)
  • TABLE 135. CHINA CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY PAIN MANAGEMENT, 2018-2030 (USD MILLION)
  • TABLE 136. CHINA CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY PSYCHIATRIC DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 137. CHINA CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 138. CHINA CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
  • TABLE 139. CHINA CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 140. CHINA CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY INJECTABLE, 2018-2030 (USD MILLION)
  • TABLE 141. CHINA CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 142. INDIA CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 143. INDIA CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY EPILEPTIC DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 144. INDIA CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY NEURODEGENERATIVE DISEASES, 2018-2030 (USD MILLION)
  • TABLE 145. INDIA CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY PAIN MANAGEMENT, 2018-2030 (USD MILLION)
  • TABLE 146. INDIA CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY PSYCHIATRIC DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 147. INDIA CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 148. INDIA CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
  • TABLE 149. INDIA CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 150. INDIA CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY INJECTABLE, 2018-2030 (USD MILLION)
  • TABLE 151. INDIA CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 152. INDONESIA CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 153. INDONESIA CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY EPILEPTIC DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 154. INDONESIA CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY NEURODEGENERATIVE DISEASES, 2018-2030 (USD MILLION)
  • TABLE 155. INDONESIA CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY PAIN MANAGEMENT, 2018-2030 (USD MILLION)
  • TABLE 156. INDONESIA CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY PSYCHIATRIC DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 157. INDONESIA CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 158. INDONESIA CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
  • TABLE 159. INDONESIA CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 160. INDONESIA CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY INJECTABLE, 2018-2030 (USD MILLION)
  • TABLE 161. INDONESIA CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 162. JAPAN CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 163. JAPAN CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY EPILEPTIC DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 164. JAPAN CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY NEURODEGENERATIVE DISEASES, 2018-2030 (USD MILLION)
  • TABLE 165. JAPAN CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY PAIN MANAGEMENT, 2018-2030 (USD MILLION)
  • TABLE 166. JAPAN CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY PSYCHIATRIC DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 167. JAPAN CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 168. JAPAN CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
  • TABLE 169. JAPAN CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 170. JAPAN CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY INJECTABLE, 2018-2030 (USD MILLION)
  • TABLE 171. JAPAN CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 172. MALAYSIA CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 173. MALAYSIA CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY EPILEPTIC DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 174. MALAYSIA CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY NEURODEGENERATIVE DISEASES, 2018-2030 (USD MILLION)
  • TABLE 175. MALAYSIA CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY PAIN MANAGEMENT, 2018-2030 (USD MILLION)
  • TABLE 176. MALAYSIA CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY PSYCHIATRIC DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 177. MALAYSIA CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 178. MALAYSIA CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
  • TABLE 179. MALAYSIA CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 180. MALAYSIA CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY INJECTABLE, 2018-2030 (USD MILLION)
  • TABLE 181. MALAYSIA CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 182. PHILIPPINES CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 183. PHILIPPINES CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY EPILEPTIC DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 184. PHILIPPINES CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY NEURODEGENERATIVE DISEASES, 2018-2030 (USD MILLION)
  • TABLE 185. PHILIPPINES CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY PAIN MANAGEMENT, 2018-2030 (USD MILLION)
  • TABLE 186. PHILIPPINES CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY PSYCHIATRIC DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 187. PHILIPPINES CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 188. PHILIPPINES CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
  • TABLE 189. PHILIPPINES CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 190. PHILIPPINES CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY INJECTABLE, 2018-2030 (USD MILLION)
  • TABLE 191. PHILIPPINES CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 192. SINGAPORE CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 193. SINGAPORE CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY EPILEPTIC DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 194. SINGAPORE CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY NEURODEGENERATIVE DISEASES, 2018-2030 (USD MILLION)
  • TABLE 195. SINGAPORE CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY PAIN MANAGEMENT, 2018-2030 (USD MILLION)
  • TABLE 196. SINGAPORE CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY PSYCHIATRIC DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 197. SINGAPORE CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 198. SINGAPORE CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
  • TABLE 199. SINGAPORE CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 200. SINGAPORE CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY INJECTABLE, 2018-2030 (USD MILLION)
  • TABLE 201. SINGAPORE CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 202. SOUTH KOREA CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 203. SOUTH KOREA CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY EPILEPTIC DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 204. SOUTH KOREA CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY NEURODEGENERATIVE DISEASES, 2018-2030 (USD MILLION)
  • TABLE 205. SOUTH KOREA CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY PAIN MANAGEMENT, 2018-2030 (USD MILLION)
  • TABLE 206. SOUTH KOREA CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY PSYCHIATRIC DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 207. SOUTH KOREA CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 208. SOUTH KOREA CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
  • TABLE 209. SOUTH KOREA CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 210. SOUTH KOREA CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY INJECTABLE, 2018-2030 (USD MILLION)
  • TABLE 211. SOUTH KOREA CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 212. TAIWAN CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 213. TAIWAN CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY EPILEPTIC DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 214. TAIWAN CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY NEURODEGENERATIVE DISEASES, 2018-2030 (USD MILLION)
  • TABLE 215. TAIWAN CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY PAIN MANAGEMENT, 2018-2030 (USD MILLION)
  • TABLE 216. TAIWAN CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY PSYCHIATRIC DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 217. TAIWAN CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 218. TAIWAN CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
  • TABLE 219. TAIWAN CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 220. TAIWAN CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY INJECTABLE, 2018-2030 (USD MILLION)
  • TABLE 221. TAIWAN CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 222. THAILAND CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 223. THAILAND CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY EPILEPTIC DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 224. THAILAND CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY NEURODEGENERATIVE DISEASES, 2018-2030 (USD MILLION)
  • TABLE 225. THAILAND CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY PAIN MANAGEMENT, 2018-2030 (USD MILLION)
  • TABLE 226. THAILAND CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY PSYCHIATRIC DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 227. THAILAND CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 228. THAILAND CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
  • TABLE 229. THAILAND CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 230. THAILAND CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY INJECTABLE, 2018-2030 (USD MILLION)
  • TABLE 231. THAILAND CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 232. VIETNAM CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 233. VIETNAM CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY EPILEPTIC DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 234. VIETNAM CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY NEURODEGENERATIVE DISEASES, 2018-2030 (USD MILLION)
  • TABLE 235. VIETNAM CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY PAIN MANAGEMENT, 2018-2030 (USD MILLION)
  • TABLE 236. VIETNAM CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY PSYCHIATRIC DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 237. VIETNAM CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 238. VIETNAM CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
  • TABLE 239. VIETNAM CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 240. VIETNAM CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY INJECTABLE, 2018-2030 (USD MILLION)
  • TABLE 241. VIETNAM CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 242. EUROPE, MIDDLE EAST & AFRICA CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 243. EUROPE, MIDDLE EAST & AFRICA CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY EPILEPTIC DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 244. EUROPE, MIDDLE EAST & AFRICA CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY NEURODEGENERATIVE DISEASES, 2018-2030 (USD MILLION)
  • TABLE 245. EUROPE, MIDDLE EAST & AFRICA CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY PAIN MANAGEMENT, 2018-2030 (USD MILLION)
  • TABLE 246. EUROPE, MIDDLE EAST & AFRICA CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY PSYCHIATRIC DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 247. EUROPE, MIDDLE EAST & AFRICA CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 248. EUROPE, MIDDLE EAST & AFRICA CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
  • TABLE 249. EUROPE, MIDDLE EAST & AFRICA CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 250. EUROPE, MIDDLE EAST & AFRICA CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY INJECTABLE, 2018-2030 (USD MILLION)
  • TABLE 251. EUROPE, MIDDLE EAST & AFRICA CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 252. EUROPE, MIDDLE EAST & AFRICA CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 253. DENMARK CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 254. DENMARK CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY EPILEPTIC DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 255. DENMARK CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY NEURODEGENERATIVE DISEASES, 2018-2030 (USD MILLION)
  • TABLE 256. DENMARK CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY PAIN MANAGEMENT, 2018-2030 (USD MILLION)
  • TABLE 257. DENMARK CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY PSYCHIATRIC DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 258. DENMARK CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 259. DENMARK CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
  • TABLE 260. DENMARK CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 261. DENMARK CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY INJECTABLE, 2018-2030 (USD MILLION)
  • TABLE 262. DENMARK CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 263. EGYPT CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 264. EGYPT CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY EPILEPTIC DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 265. EGYPT CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY NEURODEGENERATIVE DISEASES, 2018-2030 (USD MILLION)
  • TABLE 266. EGYPT CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY PAIN MANAGEMENT, 2018-2030 (USD MILLION)
  • TABLE 267. EGYPT CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY PSYCHIATRIC DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 268. EGYPT CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 269. EGYPT CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
  • TABLE 270. EGYPT CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 271. EGYPT CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY INJECTABLE, 2018-2030 (USD MILLION)
  • TABLE 272. EGYPT CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 273. FINLAND CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 274. FINLAND CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY EPILEPTIC DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 275. FINLAND CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY NEURODEGENERATIVE DISEASES, 2018-2030 (USD MILLION)
  • TABLE 276. FINLAND CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY PAIN MANAGEMENT, 2018-2030 (USD MILLION)
  • TABLE 277. FINLAND CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY PSYCHIATRIC DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 278. FINLAND CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 279. FINLAND CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
  • TABLE 280. FINLAND CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 281. FINLAND CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY INJECTABLE, 2018-2030 (USD MILLION)
  • TABLE 282. FINLAND CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 283. FRANCE CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 284. FRANCE CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY EPILEPTIC DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 285. FRANCE CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY NEURODEGENERATIVE DISEASES, 2018-2030 (USD MILLION)
  • TABLE 286. FRANCE CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY PAIN MANAGEMENT, 2018-2030 (USD MILLION)
  • TABLE 287. FRANCE CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY PSYCHIATRIC DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 288. FRANCE CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 289. FRANCE CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD